Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma

BACKGROUND: Evidence from single and multicenter phase II trials have suggested diffusion MRI is a predictive imaging biomarker for survival benefit in recurrent glioblastoma (rGBM) treated with anti-VEGF therapy. The current study confirms these findings in a large, randomized phase III clinical tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ellingson, Benjamin M, Patel, Kunal, Wang, Chencai, Raymond, Catalina, Brenner, Andrew, de Groot, John F, Butowski, Nicholas A, Zach, Leor, Campian, Jian L, Schlossman, Jacob, Rizvi, Shan, Cohen, Yael C, Lowenton-Spier, Noa, Minei, Tamar Rachmilewitz, Shmueli, Shifra Fain, Wen, Patrick Y, Cloughesy, Timothy F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350152/
https://www.ncbi.nlm.nih.gov/pubmed/34377989
http://dx.doi.org/10.1093/noajnl/vdab082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350152/
https://www.ncbi.nlm.nih.gov/pubmed/34377989
http://dx.doi.org/10.1093/noajnl/vdab082

Ejemplares similares